BioHarvest Sciences Inc. announced plans to dual-list its common shares on the Tel Aviv Stock Exchange, with trading expected to commence on September 8, 2026. The company, which already trades on the Nasdaq under the ticker BHST, will maintain the same symbol on the TASE, where it will also be listed in Hebrew as בהסט.
The dual listing covers 22,667,842 outstanding common shares, while an additional 4,516,021 shares are available for future issuance under the company’s Equity Incentive Plan. Warrants issued to investors account for 610,742 shares, and 2,564,876 options remain outstanding. The firm also has 269,521 restricted share units and 1,681,624 shares remaining available for future grants under the incentive program.
BioHarvest Sciences, an Israeli-founded botanical synthesis technology company, develops plant-based compounds through its proprietary platform. The firm operates as a contract development and manufacturing organization, producing plant-based compounds for customers while also advancing its own nutraceutical products. CEO Dr. Zaki Rakib described the dual listing as a "natural step" to broaden shareholder access and strengthen ties with the Israeli investment community.
The company will synchronize all future U.S. Securities and Exchange Commission filings via the MAGNA Disclosure System, ensuring consistent disclosure practices across both exchanges.
